S. 4494

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 4494 Introduced in Senate (IS)]

<DOC>

119th CONGRESS
2d Session
S. 4494

To prioritize funding for an expanded and sustained national investment 
in biomedical research.

_______________________________________________________________________

IN THE SENATE OF THE UNITED STATES

May 12, 2026

Mr. Durbin (for himself, Mr. Blumenthal, Ms. Duckworth, and Mr. Van 
Hollen) introduced the following bill; which was read twice and 
referred to the Committee on Appropriations

_______________________________________________________________________

A BILL

To prioritize funding for an expanded and sustained national investment 
in biomedical research.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``American Cures Act''.

SEC. 2. APPROPRIATIONS FOR INNOVATION.

(a) In General.--There are hereby authorized to be appropriated, 
and appropriated, out of any monies in the Treasury not otherwise 
appropriated, the following:
(1) National institutes of health.--For the National 
Institutes of Health at the Department of Health and Human 
Services--
(A) for fiscal year 2027, $52,467,132,000;
(B) for fiscal year 2028, $56,507,101,164;
(C) for fiscal year 2029, $60,858,147,954;
(D) for fiscal year 2030, $65,544,225,346;
(E) for fiscal year 2031, $70,591,130,698;
(F) for fiscal year 2032, $76,026,647,762;
(G) for fiscal year 2033, $81,880,699,640;
(H) for fiscal year 2034, $88,185,513,512;
(I) for fiscal year 2035, $94,975,798,052;
(J) for fiscal year 2036, $102,288,934,502; and
(K) for fiscal year 2037 and each fiscal year 
thereafter, the amount appropriated under this 
paragraph for the previous fiscal year, increased by 
the percentage increase (if any), during the previous 
fiscal year, in the Consumer Price Index for all urban 
consumers published by the Bureau of Labor Statistics.
(2) Centers for disease control and prevention.--For the 
Centers for Disease Control and Prevention at the Department of 
Health and Human Services--
(A) for fiscal year 2027,$ 9,911,621,307;
(B) for fiscal year 2028, $10,674,816,148;
(C) for fiscal year 2029, $11,496,776,991;
(D) for fiscal year 2030, $12,382,028,819;
(E) for fiscal year 2031, $13,335,445,038;
(F) for fiscal year 2032, $14,362,274,306;
(G) for fiscal year 2033, $15,468,169,428;
(H) for fiscal year 2034, $16,659,218,474;
(I) for fiscal year 2035, $17,941,978,296;
(J) for fiscal year 2036, $19,323,510,625; and
(K) for fiscal year 2037 and each fiscal year 
thereafter, the amount appropriated under this 
paragraph for the previous fiscal year, increased by 
the percentage increase (if any), during the previous 
fiscal year, in the Consumer Price Index for all urban 
consumers published by the Bureau of Labor Statistics.
(3) Research, development, test, and evaluation program of 
the department of defense health program.--For the research, 
development, test, and evaluation program of the Department of 
Defense health program--
(A) for fiscal year 2027, $2,939,358,093;
(B) for fiscal year 2028, $3,165,688,666;
(C) for fiscal year 2029, $3,409,451,694;
(D) for fiscal year 2030, $3,671,979,474;
(E) for fiscal year 2031, $3,954,721,894;
(F) for fiscal year 2032, $4,259,235,480;
(G) for fiscal year 2033, $4,587,196,612;
(H) for fiscal year 2034, $4,940,412,751;
(I) for fiscal year 2035, $5,320,824,534;
(J) for fiscal year 2036, $5,730,508,023; and
(K) for fiscal year 2037 and each fiscal year 
thereafter, the amount appropriated under this 
paragraph for the previous fiscal year, increased by 
the percentage increase (if any), during the previous 
fiscal year, in the Consumer Price Index for all urban 
consumers published by the Bureau of Labor Statistics.
(4) Medical and prosthetics research program of the 
department of veterans affairs.--For the medical and 
prosthetics research program of the Department of Veterans 
Affairs--
(A) for fiscal year 2027, $1,071,765,000;
(B) for fiscal year 2028, $1,096,132,905;
(C) for fiscal year 2029, $1,180,535,138;
(D) for fiscal year 2030, $1,271,436,344;
(E) for fiscal year 2031, $1,369,336,942;
(F) for fiscal year 2032, $1,474,775,887;
(G) for fiscal year 2033, $1,588,333,630;
(H) for fiscal year 2034, $1,710,636,320;
(I) for fiscal year 2035, $1,842,355,321;
(J) for fiscal year 2036, $1,984,218,681; and
(K) for fiscal year 2037 and each fiscal year 
thereafter, the amount appropriated under this 
paragraph for the previous fiscal year, increased by 
the percentage increase (if any), during the previous 
fiscal year, in the Consumer Price Index for all urban 
consumers published by the Bureau of Labor Statistics.
(b) Availability.--Amounts appropriated under subsection (a) shall 
remain available until expended.
(c) Definitions.--In this section:
(1) Centers for disease control and prevention.--The term 
``Centers for Disease Control and Prevention'' means the 
appropriations accounts that support the various institutes, 
offices, and centers that make up the Centers for Disease 
Control and Prevention.
(2) Research, development, test, and evaluation program of 
the department of defense health program.--The term ``research, 
development, test, and evaluation program of the Department of 
Defense health program'' means the appropriations accounts that 
support the various institutes, offices, and centers that make 
up the research, development, test, and evaluation program of 
the Department of Defense health program.
(3) Medical and prosthetics research program of the 
department of veterans affairs.--The term ``medical and 
prosthetics research program of the Department of Veterans 
Affairs'' means the appropriations accounts that support the 
various institutes, offices, and centers that make up the 
medical and prosthetics research program of the Department of 
Veterans Affairs.
(4) National institutes of health.--The term ``National 
Institutes of Health'' means the appropriations accounts that 
support the various institutes, offices, and centers that make 
up the National Institutes of Health.
(d) Exemption of Certain Appropriations From Sequestration.--
(1) In general.--Section 255(g)(1)(A) of the Balanced 
Budget and Emergency Deficit Control Act (2 U.S.C. 
905(g)(1)(A)) is amended by inserting after ``Advances to the 
Unemployment Trust Fund and Other Funds (16-0327-0-1-600).'' 
the following:
``Appropriations under the American Cures 
Act.''.
(2) Applicability.--The amendment made by this section 
shall apply to any sequestration order issued under the 
Balanced Budget and Emergency Deficit Control Act of 1985 (2 
U.S.C. 900 et seq.) on or after the date of enactment of this 
Act.
(e) Budgetary Effects.--
(1) Statutory paygo scorecards.--The budgetary effects of 
this section shall not be entered on either PAYGO scorecard 
maintained pursuant to section 4(d) of the Statutory Pay-As-
You-Go Act of 2010 (2 U.S.C. 933(d)).
(2) Senate paygo scorecards.--The budgetary effects of this 
section shall not be entered on any PAYGO scorecard maintained 
for purposes of section 4106 of H. Con. Res. 71 (115th 
Congress).
<all>